RecruitingPhase 2/3

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

United States342 participantsStarted 2026-03-19

Plain-language summary

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
✕. High risk of thrombosis or cardiovascular disease
✕. High risk of herpes zoster
✕. Active or recent infection

Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24

Timeframe: Week 24

NCT IDNCT07532603

SponsorPriovant Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-12-31

Clinical Trial Administrator